Literature DB >> 17587559

Adherence to treatment by patients with asthma or COPD: comparison between inhaled drugs and transdermal patch.

Gen Tamura1, Ken Ohta.   

Abstract

An Internet-based questionnaire study involving patients with asthma and chronic obstructive pulmonary disease (COPD) and parents of children with asthma was conducted to evaluate adherence to treatment, and convenience of inhalation and transdermal formulations. Valid responses were obtained from 1470 patients. Among asthmatic patients, the percentage of those who selected "taking as prescribed" was 52.7% for inhalant users and 83.2% for transdermal users. Among patients with COPD, the corresponding values were 54.7% and 86.6%. There was a significant difference (p<0.01) in treatment compliance between inhalation and transdermal formulations in both groups. The most common reason for poor adherence was "frequency of administration", and 83.2% of the patients preferred a once-daily administration. In addition, patients who had used both types of formulations preferred the transdermal ones. In conclusion, health care professionals should further educate their patients about the importance of treatment with inhalants, since poor adherence to treatment with inhalation formulations significantly hinders achievement of optimal efficacy. In addition, transdermal tulobuterol patch, which is administered once daily as a long-acting, beta(2)-agonist, appeared to be useful for long-term control of both asthma and COPD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17587559     DOI: 10.1016/j.rmed.2007.05.001

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  19 in total

1.  Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study.

Authors:  Gregory Feldman; Thomas Siler; Niyati Prasad; Damon Jack; Simon Piggott; Roger Owen; Mark Higgins; Benjamin Kramer
Journal:  BMC Pulm Med       Date:  2010-03-08       Impact factor: 3.317

Review 2.  Inhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary disease.

Authors:  Natalie J Carter
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

Review 3.  Turning a molecule into a medicine: the development of indacaterol as a novel once-daily bronchodilator treatment for patients with COPD.

Authors:  Lorraine Murphy; Stephen Rennard; James Donohue; Mathieu Molimard; Ronald Dahl; Kai-Michael Beeh; Juergen Dederichs; Hans-Jürgen Fülle; Mark Higgins; David Young
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

Review 4.  Novel long-acting bronchodilators for COPD and asthma.

Authors:  M Cazzola; M G Matera
Journal:  Br J Pharmacol       Date:  2008-07-07       Impact factor: 8.739

5.  Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis.

Authors:  Shannon Cope; Jie Zhang; James Williams; Jeroen P Jansen
Journal:  BMC Pulm Med       Date:  2012-06-25       Impact factor: 3.317

6.  Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data.

Authors:  Eugene R Bleecker; Thomas Siler; Roger Owen; Benjamin Kramer
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2011-08-18

7.  Assessment of dog owner adherence to veterinarians' flea and tick prevention recommendations in the United States using a cross-sectional survey.

Authors:  Robert P Lavan; Kaan Tunceli; Dongmu Zhang; Dorothy Normile; Rob Armstrong
Journal:  Parasit Vectors       Date:  2017-06-06       Impact factor: 3.876

Review 8.  Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD.

Authors:  Roland Buhl; Donald Banerji
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-10-26

9.  Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study.

Authors:  Eric D Bateman; Gary T Ferguson; Neil Barnes; Nicola Gallagher; Yulia Green; Michelle Henley; Donald Banerji
Journal:  Eur Respir J       Date:  2013-05-30       Impact factor: 16.671

Review 10.  Switching treatments in COPD: implications for costs and treatment adherence.

Authors:  Fulvio Braido; Federico Lavorini; Francesco Blasi; Ilaria Baiardini; Giorgio Walter Canonica
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.